+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021

  • ID: 5359575
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 2055 pages
  • Global Markets Direct

FEATURED COMPANIES

  • 1st Bio Therapeutics Inc
  • BeyondBio Inc
  • CuroNZ Ltd
  • MGC Pharmaceuticals Ltd
  • Orphi Therapeutics Inc
  • VectorY Therapeutics Inc
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease (Central Nervous System) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 23, 62, 86, 1, 4, 358, 178 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 3, 107 and 52 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 1st Bio Therapeutics Inc
  • BeyondBio Inc
  • CuroNZ Ltd
  • MGC Pharmaceuticals Ltd
  • Orphi Therapeutics Inc
  • VectorY Therapeutics Inc
  • MORE
  • Introduction
  • Alzheimer's Disease - Overview
  • Alzheimer's Disease - Therapeutics Development
  • Alzheimer's Disease - Therapeutics Assessment
  • Alzheimer's Disease - Companies Involved in Therapeutics Development
  • Alzheimer's Disease - Drug Profiles
Alzheimer's Disease - Dormant Projects

Alzheimer's Disease - Discontinued Products
  • Alzheimer's Disease - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Alzheimer's Disease, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Alzheimer's Disease - Pipeline by 1st Bio Therapeutics Inc, 2021
  • Alzheimer's Disease - Pipeline by 2A Pharma AB, 2021
  • Alzheimer's Disease - Pipeline by 4B Technologies (Suzhou) Co Ltd, 2021
  • Alzheimer's Disease - Pipeline by 4P-Pharma SAS, 2021
  • Alzheimer's Disease - Pipeline by AB Science SA, 2021
  • Alzheimer's Disease - Pipeline by Abaxy Sprl, 2021
  • Alzheimer's Disease - Pipeline by AbbVie Inc, 2021
  • Alzheimer's Disease - Pipeline by Abrexa Pharmaceuticals Inc, 2021
  • Alzheimer's Disease - Pipeline by AC Immune SA, 2021
  • Alzheimer's Disease - Pipeline by Acadia Pharmaceuticals Inc, 2021
  • Alzheimer's Disease - Pipeline by Accuitis Pharmaceuticals Inc, 2021
  • Alzheimer's Disease - Pipeline by Acelot Inc, 2021
  • Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, 2021
  • Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, 2021
  • Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, 2021
  • Alzheimer's Disease - Pipeline by ADEL Inc, 2021
  • Alzheimer's Disease - Pipeline by Adocia SAS, 2021
  • Alzheimer's Disease - Pipeline by ADRx Inc, 2021
  • Alzheimer's Disease - Pipeline by Aerobyx LLC, 2021
  • Alzheimer's Disease - Pipeline by Aeton Therapeutics Inc, 2021
  • Alzheimer's Disease - Pipeline by AfaSci Inc, 2021
  • Alzheimer's Disease - Pipeline by AIBIOS Co Ltd, 2021
  • Alzheimer's Disease - Pipeline by Akome Biotech Ltd, 2021
  • Alzheimer's Disease - Pipeline by Alector Inc, 2021
  • Alzheimer's Disease - Pipeline by Alfasigma SpA, 2021
  • Alzheimer's Disease - Pipeline by Alkahest Inc, 2021
  • Alzheimer's Disease - Pipeline by Alkermes Plc, 2021
  • Alzheimer's Disease - Pipeline by Allyx Therapeutics Inc, 2021
  • Alzheimer's Disease - Pipeline by Alnylam Pharmaceuticals Inc, 2021
  • Alzheimer's Disease - Pipeline by AlphaCognition Inc, 2021
  • Alzheimer's Disease - Pipeline by Alsonex Pty Ltd, 2021
  • Alzheimer's Disease - Pipeline by Longeveron Inc, 2021
  • Alzheimer's Disease - Pipeline by LSL Neurosciences LLC, 2021
  • Alzheimer's Disease - Pipeline by Lyndra Therapeutics Inc., 2021
  • Alzheimer's Disease - Pipeline by Madera BioSciences Inc, 2021
  • Alzheimer's Disease - Pipeline by Magnolia Neurosciences Corp, 2021
  • Alzheimer's Disease - Pipeline by ManRos Therapeutics, 2021
  • Alzheimer's Disease - Pipeline by MapLight therapeutics Inc, 2021
  • Alzheimer's Disease - Pipeline by MaxiVAX SA, 2021
  • Alzheimer's Disease - Pipeline by MD Healthcare Inc, 2021
  • Alzheimer's Disease - Pipeline by MDimune Inc, 2021
  • Alzheimer's Disease - Pipeline by MedBiome Inc, 2021
  • Alzheimer's Disease - Pipeline by Medesis Pharma SA, 2021
  • Alzheimer's Disease - Pipeline by Medifron DBT Co Ltd, 2021
  • Alzheimer's Disease - Pipeline by medilabo RFP Inc, 2021
  • Alzheimer's Disease - Pipeline by MEDRx Co Ltd, 2021
  • Alzheimer's Disease - Pipeline by MegaNano BioTech Inc, 2021
  • Alzheimer's Disease - Pipeline by MEI Pharma Inc, 2021
  • Alzheimer's Disease - Pipeline by Mercia Pharma Inc, 2021
  • Alzheimer's Disease - Pipeline by Merck & Co Inc, 2021
  • Alzheimer's Disease - Pipeline by MetiMedi Pharmaceuticals Co Ltd, 2021
  • Alzheimer's Disease - Pipeline by MetrioPharm AG, 2021
  • Alzheimer's Disease - Pipeline by MetVital Inc, 2021
  • Alzheimer's Disease - Pipeline by MGC Pharmaceuticals Ltd, 2021
  • Alzheimer's Disease - Pipeline by Mindset Pharma Inc, 2021
  • Alzheimer's Disease - Pipeline by Mission Therapeutics Ltd, 2021
  • Alzheimer's Disease - Pipeline by Mitoconix Bio Ltd, 2021
  • Alzheimer's Disease - Pipeline by Modag GmbH, 2021
  • Alzheimer's Disease - Pipeline by Montisera Ltd, 2021
  • Alzheimer's Disease - Pipeline by NAL Pharmaceuticals Ltd, 2021
  • Alzheimer's Disease - Pipeline by Nanomerics Ltd, 2021
  • Alzheimer's Disease - Pipeline by NatureWise Biotech & Medicals Corp, 2021
  • Alzheimer's Disease - Pipeline by Neonc Technologies Inc, 2021
  • Alzheimer's Disease - Pipeline by NeoNeuro SAS, 2021
  • Alzheimer's Disease - Pipeline by NeoProgen Inc, 2021
  • Alzheimer's Disease - Pipeline by NervGen Pharma Corp, 2021
  • Alzheimer's Disease - Pipeline by NeuExcell Therapeutics Inc, 2021
  • Alzheimer's Disease - Pipeline by Neuracle Science Co Ltd, 2021
  • Alzheimer's Disease - Pipeline by Neuraly Inc, 2021
List of Figures
  • Number of Products under Development for Alzheimer's Disease, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • 1st Bio Therapeutics Inc
  • 2A Pharma AB
  • 4B Technologies (Suzhou) Co Ltd
  • 4P-Pharma SAS
  • AB Science SA
  • Abaxy Sprl
  • AbbVie Inc
  • Abrexa Pharmaceuticals Inc
  • AC Immune SA
  • Acadia Pharmaceuticals Inc
  • Accuitis Pharmaceuticals Inc
  • Acelot Inc
  • Actinogen Medical Ltd
  • Acumen Pharmaceuticals Inc
  • Addex Therapeutics Ltd
  • ADEL Inc
  • Adocia SAS
  • ADRx Inc
  • Aerobyx LLC
  • Avidin Biotechnology Ltd
  • Avineuro Pharmaceuticals Inc
  • Axon Neuroscience SE
  • Axxam SpA
  • AZTherapies Inc
  • Berg LLC
  • BeyondBio Inc
  • Bio-Pharm Solutions Co Ltd
  • BioArctic AB
  • Biogen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • Biom Therapeutics LLC
  • Biorchestra Ltd
  • BioSplice Therapeutics Inc
  • BioVie Inc
  • BioXcel Therapeutics Inc
  • Bisichem Co Ltd
  • Boehringer Ingelheim International GmbH
  • Bolden Therapeutics Inc
  • Bolder Biotechnology Inc
  • Boryung Pharmaceutical Co Ltd
  • Brain Innovation Co Ltd
  • BrainStorm Cell Therapeutics Inc
  • Brainvectis SAS
  • Corium Inc
  • Cortexyme Inc
  • Cortice Biosciences Inc
  • Covalent Bioscience Inc
  • Coya Therapeutics Inc
  • Creative Bio-Peptides Inc
  • Crossbeta Biosciences BV
  • CuroNZ Ltd
  • Cyclerion Therapeutics Inc
  • Cyclo Therapeutics Inc
  • CycloLab Cyclodextrin Research and Development Laboratory Ltd
  • Dadang & BIO Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Immunwork Inc
  • Inmune Bio Inc
  • InnoBioscience LLC
  • InnoPharmaScreen Inc
  • Kwang Dong Pharmaceutical Co Ltd
  • Kyowa Kirin Co Ltd
  • Lacerta Therapeutics Inc
  • Landos Biopharma Inc
  • Lauren Sciences LLC
  • Lead Discovery Center GmbH
  • LEXEO Therapeutics LLC
  • Libella Gene Therapeutics
  • Light Chain Bioscience
  • Longeveron Inc
  • LSL Neurosciences LLC
  • Lyndra Therapeutics Inc.
  • MetrioPharm AG
  • MetVital Inc
  • MGC Pharmaceuticals Ltd
  • Mindset Pharma Inc
  • Mission Therapeutics Ltd
  • Mitoconix Bio Ltd
  • Modag GmbH
  • Montisera Ltd
  • NAL Pharmaceuticals Ltd
  • Nanomerics Ltd
  • NatureWise Biotech & Medicals Corp
  • Neonc Technologies Inc
  • NeoNeuro SAS
  • NeoProgen Inc
  • NervGen Pharma Corp
  • NeuExcell Therapeutics Inc
  • Neuracle Science Co Ltd
  • Oleolive LLC
  • Oligomerix inc
  • OncoSynergy Inc
  • Ono Pharmaceutical Co Ltd
  • Opsona Therapeutics Ltd
  • Orpheris Inc
  • Orphi Therapeutics Inc
  • Oryzon Genomics SA
  • OTR3 SAS
  • Overseas Pharmaceuticals Ltd
  • Oxstem Ltd
  • P2D Inc
  • Palisade Bio, Inc
  • Panorama Researchama Research
  • Paramag Biosciences
  • Transposon Therapeutics Inc
  • Treeway BV
  • Treventis Corp
  • Tria Bioscience Corp
  • Triplet Therapeutics Inc
  • TrueBinding Inc
  • UCB SA
  • Uni-Bio Science Group Ltd
  • Unity Biotechnology Inc
  • USA Elixiria Biotech Inc
  • Vaccinex Inc
  • Vanworld Pharmaceutical (Rugao) Company Ltd
  • Varinel Inc
  • Vaxxinity Inc
  • VectorY Therapeutics Inc
  • VFP Therapies
  • Videns Incorp Ltd
  • Virogenics Inc
  • Vitruvian Biomedical Inc
  • Vivoryon Therapeutics NV
  • Vivreon Biosciences LLC
  • Voronoi Group
  • Voyager Therapeutics Inc
  • Vybion Inc
  • Whan In Pharm Co Ltd
  • Wren Therapeutics Ltd
  • Xcelthera INC
  • Xenexus Pharmaceuticals Pty Ltd
  • Xigen SA
  • Xonovo Inc
  • Yasham P2D Lifesciences Pvt Ltd
  • Yuhan Corp
  • Yuma Therapeutics Corp
  • Yumanity Therapeutics Inc
  • Zensun (Shanghai) Sci & Tech Co Ltd
  • Zhejiang Hisun Pharmaceutical Co Ltd
  • Zhejiang Huahai Pharmaceutical Co Ltd
  • Zhittya Genesis Medicine Inc
  • ZZ Biotech LLC
Note: Product cover images may vary from those shown
Adroll
adroll